Reclast for Osteoporosis: How Once-Yearly Infusions Work

Reclast is the brand name for zoledronic acid, a bisphosphonate given as a single intravenous infusion once a year to treat osteoporosis. In clinical trials, it cut the risk of clinical fractures by about a third compared to placebo and increased bone mineral density at the hip and spine over three to six years of treatment.¹ Its once-yearly dosing sets it apart from oral bisphosphonates that require weekly or monthly pills, and the drug’s unusually long residence time in bone means its effects persist well beyond the last infusion.

How Reclast Works in Bone

Zoledronic acid has an extremely strong chemical attraction to calcified tissue. Animal studies show it concentrates in bone at levels several orders of magnitude higher than in soft tissue, with particularly strong uptake in the spine and other parts of the axial skeleton.² Once bound to bone mineral, the drug is gradually taken up by osteoclasts, the cells responsible for breaking down old bone. Inside those cells, it disrupts a key enzyme pathway, effectively slowing osteoclast activity and reducing the rate of bone turnover. Because the drug embeds itself in the bone matrix and is released slowly over years, a single 5 mg infusion delivered over at least 15 minutes provides a full year of activity. That long half-life in bone is the pharmacological basis for the once-yearly schedule.³

Fracture Prevention in Postmenopausal Women

The cornerstone evidence for Reclast comes from two large trials. In the HORIZON Pivotal Fracture Trial, postmenopausal women with osteoporosis who received yearly infusions for three years had substantially fewer fractures than those who received a placebo. A subgroup analysis of women aged 75 and older found that the rate of any clinical fracture dropped from about 17% in the placebo group to about 11% in the zoledronic acid group. Clinical vertebral fractures fell even more sharply, from roughly 4% to 1%.⁴ Those are meaningful real-world numbers: for every hundred older women treated for three years, roughly six fewer experienced a fracture of some kind.

Continuing treatment beyond three years provides additional, though smaller, gains. Extension data out to six years showed that women who stayed on zoledronic acid had a lower risk of vertebral fractures and higher bone density than those who switched to placebo at year three. Beyond six years, though, the incremental benefit was minimal.⁵ This plateau is one reason clinicians now discuss drug holidays rather than open-ended treatment.

The Mortality Benefit After Hip Fracture

Perhaps the most striking finding in the Reclast literature has nothing to do with bone density. The HORIZON Recurrent Fracture Trial enrolled patients who had recently undergone surgical repair of a hip fracture and randomized them to yearly zoledronic acid or placebo. Over roughly two years of follow-up, the drug reduced new clinical fractures by about 35%. But the headline result was a 28% reduction in death from any cause: about 10% of patients in the zoledronic acid group died, compared with about 13% in the placebo group.⁶

That mortality benefit surprised researchers, and a follow-up analysis tried to figure out what was driving it. The obvious candidate, preventing a second fracture that leads to decline and death, turned out to explain only about 8% of the effect. When the investigators looked more closely, zoledronic acid-treated patients were less likely to die from pneumonia and from cardiac arrhythmias, suggesting the drug may have effects beyond bone. Whether this reflects something about reduced immobility, reduced inflammation, or some direct pharmacological action on blood vessels or immune cells remains an open question.⁷ No other osteoporosis treatment has a comparable mortality finding in a randomized trial, which makes this result both exciting and hard to generalize.

What to Expect on Infusion Day

The infusion itself is straightforward: you sit in a clinic chair for at least 15 minutes while the drug is delivered through an IV. What catches many people off guard is the flu-like reaction that can follow. Muscle aches, low-grade fever, headache, and joint pain are common within the first one to three days. These symptoms are driven by a spike in inflammatory signaling molecules that peaks around 24 hours and fades by about 72 hours.⁸ The reaction is most pronounced after the first infusion and tends to be milder or absent with subsequent yearly doses. Taking acetaminophen around the time of the infusion can blunt the symptoms.

Being well hydrated before and after the infusion matters. Zoledronic acid is cleared by the kidneys, and inadequate hydration raises the risk of acute kidney injury. In one study that tracked kidney function after nearly a thousand infusions, acute kidney injury within 14 days occurred after about 5% of them, though most cases were mild and transient.⁹ Reclast is not recommended for people whose kidney function is already significantly impaired.

Calcium, Vitamin D, and Pre-Infusion Checks

Zoledronic acid works by slowing the release of calcium from bone, which means it can push blood calcium levels down. If you go into an infusion already low in calcium or vitamin D, the drop can become clinically significant, causing numbness, tingling, muscle cramps, or in rare cases, more serious symptoms.¹⁰ To minimize that risk, prescribers are advised to check serum calcium levels and correct any deficiency before scheduling the infusion, ensure adequate vitamin D supplementation before and after, and monitor calcium along with related markers like phosphate and magnesium after the infusion.¹¹ In practice, many clinicians will start patients on calcium and vitamin D supplements for several weeks before the first infusion.

Rare but Serious Risks

Two rare complications get the most attention in discussions about any bisphosphonate: osteonecrosis of the jaw and atypical femur fractures. Both are uncommon enough that they should not deter most patients from treatment, but worth understanding.

Osteonecrosis of the jaw is a condition where a patch of jawbone fails to heal properly, usually after a dental procedure like an extraction. The risk for patients on osteoporosis-dose bisphosphonates is estimated at roughly 1 in 10,000 to 1 in 100,000, though it may rise to around 1 in 300 in the period following a dental extraction. The vast majority of cases have historically occurred in patients receiving much higher, more frequent intravenous doses for cancer treatment rather than the once-yearly osteoporosis regimen.¹² Getting a dental checkup before starting Reclast and informing your dentist that you are on the drug remain sensible precautions.

Atypical femur fractures are unusual breaks that occur in the thigh bone below the hip joint, often with minimal trauma and sometimes preceded by weeks of dull aching pain in the thigh. A European working group estimated the rate at roughly one per 1,000 patients per year of bisphosphonate use, with risk accumulating the longer someone stays on therapy.¹³ In case series, these fractures have been reported with both oral and intravenous bisphosphonates.¹⁴ The rising risk over time is one of the main arguments for taking a treatment break after several years.

Drug Holidays and How Long to Treat

Because zoledronic acid binds so tightly to bone and releases slowly, you don’t lose all protection the moment treatment stops. Bone turnover markers can stay suppressed and bone density can remain at or above baseline levels for years after the last infusion. One study followed women who received a single 5 mg dose and found that a marker of bone breakdown remained at least 25% lower than in untreated women for nine years.¹⁵ That is a remarkably long tail of activity.

Current recommendations generally support a drug holiday of two to three years for most patients after three to six years of bisphosphonate treatment, particularly for those at low to moderate fracture risk.¹⁶ During the holiday, bone density and turnover markers are monitored every one to three years. If markers start rising or a new fracture occurs, treatment can be restarted.¹⁷ Patients at high fracture risk, such as those with very low bone density or a recent fragility fracture, are often kept on therapy without interruption because the risk of a new fracture outweighs the small chance of a rare complication.¹⁸

Controversy remains about exactly when to start a holiday and how long it should last. The evidence is drawn mostly from extensions of the original pivotal trials rather than from new randomized comparisons specifically designed to test holiday strategies. Decisions end up being individualized, balancing bone density, fracture history, age, and the trajectory of turnover markers.¹⁹

Why Once-Yearly Dosing Matters for Adherence

Osteoporosis medications only work if patients actually take them, and adherence to oral bisphosphonates is notoriously poor. Many people prescribed weekly or monthly pills stop within a year, either because they forget, find the dosing instructions burdensome (oral bisphosphonates typically require fasting and staying upright for 30 minutes), or experience gastrointestinal side effects. With Reclast, the treatment happens in a clinical setting once a year, which removes the daily or weekly compliance question entirely. The limited data available suggest that adherence is improved with the annual intravenous regimen.²⁰

Patient preference surveys reinforce this. When asked whether they would choose annual intravenous therapy or weekly pills, roughly two-thirds to nearly 80% of patients chose the infusion, even among those who experienced the flu-like post-infusion symptoms.²¹ ²² That said, showing up for the second and third infusions in subsequent years is not guaranteed. A recent analysis found that many real-world patients never return for their second dose, particularly those without a prior history of oral bisphosphonate use, suggesting that the once-yearly convenience does not fully solve the persistence problem.²³

How Reclast Compares to Denosumab

The most common alternative to Reclast for patients who need something beyond oral pills is denosumab (Prolia), a biologic injection given every six months. The two drugs work differently: zoledronic acid inhibits the bone-dissolving cells directly, while denosumab blocks a signaling protein that recruits and activates those cells. In a head-to-head comparison, denosumab produced a larger gain in spine bone density at one year, though the difference at the hip was not statistically significant.²⁴

The practical difference between the two comes down to what happens when you stop. Denosumab’s effects reverse rapidly after discontinuation: bone turnover surges and bone density drops, sometimes quickly enough to cause rebound vertebral fractures. Patients who stop denosumab almost always need to transition to a bisphosphonate to prevent that rebound. Reclast has the opposite profile. Its effects linger for years after the last dose, making treatment breaks much simpler. For patients who might have trouble returning for regular appointments, that long tail of action is a genuine advantage.

From a cost perspective, a Japanese cost-effectiveness analysis found that three years of annual zoledronic acid was actually cost-saving compared with a sequential strategy of three years of denosumab followed by three years of oral alendronate, producing better outcomes at lower total cost.²⁵ Cost comparisons are always specific to the healthcare system and pricing involved, but the simplicity of the Reclast regimen, with its lack of a mandatory follow-on therapy, gives it a structural economic advantage.

Reclast in Men With Osteoporosis

Osteoporosis is underdiagnosed and undertreated in men, partly because of the outdated perception that it is a women’s disease. About one in four hip fractures in older adults occurs in men, and the mortality rate after hip fracture is actually higher in men than in women. Zoledronic acid is approved in the United States for the treatment of osteoporosis in men, based on evidence that it increases bone density and suppresses bone turnover in the same way it does in postmenopausal women.²⁶ The fracture-reduction data in men are thinner than in women simply because fewer men have been enrolled in large trials, but the biological mechanism is the same and the treatment approach mirrors what is done for women.

When Reclast Is Not the Right Choice

Reclast is not suitable for everyone with osteoporosis. People with significantly impaired kidney function are generally excluded because the drug is cleared renally and can worsen kidney damage. Those with uncorrected low calcium or vitamin D should not receive the infusion until their levels are normalized. Pregnant or breastfeeding women should avoid it, and anyone with a known allergy to zoledronic acid or other bisphosphonates is ruled out.

For patients who have already experienced an atypical femur fracture or jaw osteonecrosis on a bisphosphonate, a non-bisphosphonate alternative like denosumab, romosozumab, or teriparatide would typically be chosen instead. Similarly, patients whose osteoporosis is severe and who need rapid bone formation rather than just slower bone breakdown may be started on an anabolic agent like teriparatide or romosozumab first, with Reclast used afterward to maintain the gains. This “build then protect” sequencing has become increasingly common in clinical practice for high-risk patients.

Finally, the practical reality of needing a clinical visit for the infusion can be a barrier. People in rural areas or those with limited mobility may find yearly trips to an infusion center difficult. For them, the once-yearly convenience is offset by the logistics of access, and an oral bisphosphonate filled at a local pharmacy might be more realistic despite its adherence challenges.